Montz Harcus Wealth Management LLC Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Montz Harcus Wealth Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,733 shares of the company’s stock after selling 211 shares during the quarter. Montz Harcus Wealth Management LLC’s holdings in Johnson & Johnson were worth $253,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of JNJ. Christopher J. Hasenberg Inc purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $31,000. WFA Asset Management Corp lifted its position in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at approximately $44,000. Disciplined Equity Management Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth about $45,000. Finally, Grayhawk Investment Strategies Inc. grew its holdings in shares of Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after purchasing an additional 259 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on JNJ shares. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday. Finally, TD Cowen lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Price Performance

NYSE JNJ opened at $159.60 on Tuesday. The company has a market cap of $384.11 billion, a price-to-earnings ratio of 9.95, a PEG ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock’s fifty day moving average price is $152.63 and its 200 day moving average price is $153.07. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $169.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the company earned $2.80 earnings per share. The company’s revenue was up 4.3% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.11%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.